<DOC>
	<DOCNO>NCT01178151</DOCNO>
	<brief_summary>In pilot study investigator treat patient know Peutz-Jeghers syndrome ( PJS ) diagnose advanced malignancy everolimus 10mg daily disease progression . Most patient PJS inherit LKB1 mutation lead aberrant m-TOR activity . Their risk develop malignancy intestinal polyp probably related constitutive mTOR signal . The hypothesis mTOR inhibition effective anticancer treatment PJS patient advanced malignancy .</brief_summary>
	<brief_title>Study Everolimus Treatment Advanced Malignancies Patients With Peutz-Jeghers Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Peutz-Jeghers Syndrome</mesh_term>
	<mesh_term>Neoplastic Processes</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Tow cohort PJS patient include . Cohort 1 : Advanced malignancy Cohort 2 : High risk polyp General inclusion criterion : 1 . Known PeutzJeghers disease ( LKB1 mutation ) 2 . No concurrent systemic anti cancer treatment 3 . No prior treatment mTOR inhibitor 4 . Prior malignancy concurrent second malignancy allow 5 . Prior systemic therapy permit washout time least 4 week 6 . ECOG/ WHO performance 02 7 . Age &gt; 18 year 8 . Adequate renal function ( defined creatinine &lt; 150 Î¼mol/L ) 9 . Adequate liver function ( bilirubin &lt; 1.5 time upper limit normal , ALAT ASAT &lt; 5.0 time upper limit normal case liver metastases &lt; 2.5 upper limit normal absence liver metastases 10 . Adequate bone marrow function ( WBC &gt; 3.0 x 10 9/L , platelet &gt; 100 x 10 9/L ) 11 . Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial . 12 . No pregnancy lactate ifof childbearing potential patient must agree use reliable contraceptive method throughout study 13 . No serious concomitant systemic disorder would compromise safety patient , discretion investigator 14 . Signed informed consent accord ICH/GCP . 15 . No uncontrolled symptomatic hyperglycaemia Specific inclusion criterion cohort 1 : 1 . Cytological histological confirm carcinoma 2 . Metastatic nonresectable disease 3 . Patients clinically and/or radiographically document measurable lesion accord RECIST criterion : 1 . Xray , physical exam &gt; 20 mm 2 . Spiral CT scan &gt; 10 mm 3 . Nonspiral CT scan &gt; 20 mm Specific inclusion criterion cohort 2 : 1 . Known high risk polyp ( definition see page 19 ) 2 . Ability undergo endoscopy Specific Exclusion criterion : Symptomatic PJpolyps , define polyp likely responsible/causal abdominal symptom patient present .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Peutz-Jeghers syndrome</keyword>
	<keyword>mTOR inhibition</keyword>
	<keyword>cancer</keyword>
</DOC>